{"analyses":[{"ciPctValue":"95","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.1137","pValueComment":"Test comparison for baseline level.","statisticalMethod":"Kruskal-Wallis","testedNonInferiority":false},{"ciPctValue":"95","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8042","pValueComment":"Test comparison for week 7 level.","statisticalMethod":"Kruskal-Wallis","testedNonInferiority":false},{"ciPctValue":"95","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2016","pValueComment":"Test comparison for week 16 level.","statisticalMethod":"Kruskal-Wallis","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.92","value":"90.0"},{"groupId":"OG001","spread":"9.05","value":"88.5"},{"groupId":"OG002","spread":"8.19","value":"90.1"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.21","value":"93.0"},{"groupId":"OG001","spread":"9.70","value":"92.3"},{"groupId":"OG002","spread":"8.56","value":"92.8"}]}],"title":"Week 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.37","value":"94.0"},{"groupId":"OG001","spread":"7.55","value":"94.4"},{"groupId":"OG002","spread":"9.31","value":"92.3"}]}],"title":"Week 16"}],"denoms":[{"counts":[{"groupId":"OG000","value":"164"},{"groupId":"OG001","value":"163"},{"groupId":"OG002","value":"163"}],"units":"Participants"}],"description":"MCV is a measure of the average red blood cell volume.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive darbepoetin alfa (DA) subcutaneously and sodium ferric gluconate complex intravenously (IV) over 90 minutes on day 1. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.","id":"OG000","title":"DA + IV Iron"},{"description":"Patients receive darbepoetin alfa (DA) as in arm I and oral ferrous sulfate once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.","id":"OG001","title":"DA + Oral Iron"},{"description":"Patients receive darbepoetin alfa (DA) as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for up to 15 weeks in the absence of unacceptable toxicity.","id":"OG002","title":"DA + Placebo"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline, 7 weeks and 16 weeks","title":"Mean Corpuscular Volume (MCV) Level at Baseline, Week 7 and Week 16","type":"SECONDARY","unitOfMeasure":"fL"}